Aquestive Therapeutics (AQST) EV to FCF (2018 - 2026)

Aquestive Therapeutics has reported EV to FCF for 9 years, with the latest figure at 43.89 in Q2 2026.

• On a quarterly basis, EV to FCF fell 31.19% year-over-year to 43.89 in Q2 2026; TTM through Jun 2026 was 9.22, a 71.87% decrease from a year earlier, with the FY2025 full-year figure at 12.59, down 78.13% from the prior year.
• EV to FCF was 43.89 for Q2 2026 at Aquestive Therapeutics, down from 27.26 in the prior quarter.
• The five-year high for EV to FCF was 17.11 in Q3 2022, with the low at 78.0 in Q4 2025.
• Average EV to FCF over 5 years is 21.94, with a median of 22.04 recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: EV to FCF surged 209.02% in 2022, then tumbled 973.79% in 2023.
• Over 5 years, EV to FCF stood at 2.64 in 2022, then sank by 973.79% to 23.11 in 2023, then tumbled by 68.93% to 39.04 in 2024, then tumbled by 99.83% to 78.0 in 2025, then soared by 43.74% to 43.89 in 2026.
• The last three EV to FCF figures came in at 43.89 (Q2 2026), 27.26 (Q1 2026), and 78.0 (Q4 2025), per Business Quant data.